71 related articles for article (PubMed ID: 6300501)
1. Cell-destructive activity in the serum of a tumor patient after infusion of alkyl lysophospholipid.
Andreesen R; Munder PG
J Natl Cancer Inst; 1983 Apr; 70(4):623-7. PubMed ID: 6300501
[TBL] [Abstract][Full Text] [Related]
2. Studies on various parameters influencing leukemic cell destruction by alkyl-lysophospholipids.
Andreesen R; Modolell M; Oepke GH; Common H; Löhr GW; Munder PG
Anticancer Res; 1982; 2(1-2):95-100. PubMed ID: 7114806
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity in the serum of a patient with metastasizing nephroblastoma given intravenous infusions of alkyl-lysophospholipids in a phase I study.
Andreesen R; Arnold H; Löhr GW
Blut; 1982 Feb; 44(2):79-82. PubMed ID: 6277413
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of thioether-lysophospholipids in leukemias and tumors of human origin.
Berdel WE; Fromm M; Fink U; Pahlke W; Bicker U; Reichert A; Rastetter J
Cancer Res; 1983 Nov; 43(11):5538-43. PubMed ID: 6577950
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of alkyl-lysophospholipid derivatives and low-alkyl-cleavage enzyme activities in rat brain tumor cells.
Berdel WE; Greiner E; Fink U; Stavrou D; Reichert A; Rastetter J; Hoffman DR; Snyder F
Cancer Res; 1983 Feb; 43(2):541-5. PubMed ID: 6848177
[TBL] [Abstract][Full Text] [Related]
6. Effects of alkyl-lysophospholipids on human leukemic cell lines measured by nuclear magnetic resonance.
Long RC; Small WC; Brynes RK; Tidwell T; Goldstein JH; Vogler WR
Cancer Res; 1983 Feb; 43(2):770-5. PubMed ID: 6571718
[TBL] [Abstract][Full Text] [Related]
7. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids.
Modolell M; Andreesen R; Pahlke W; Brugger U; Munder PG
Cancer Res; 1979 Nov; 39(11):4681-6. PubMed ID: 498095
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of leukemia cell lines to cytotoxic alkyl-lysophospholipids in relation to O-alkyl cleavage enzyme activities.
Unger C; Eibl H; Kim DJ; Fleer EA; Kötting J; Bartsch HH; Nagel GA; Pfizenmaier K
J Natl Cancer Inst; 1987 Feb; 78(2):219-22. PubMed ID: 3468284
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor action of alkyl-lysophospholipids (Review).
Berdel WE; Bausert WR; Fink U; Rastetter J; Munder PG
Anticancer Res; 1981; 1(6):345-52. PubMed ID: 7046622
[TBL] [Abstract][Full Text] [Related]
10. Temperature dependence of leukemic cell destruction by alkyl-lysophospholipids (NSC 324368).
Andreesen R; Modolell M; Oepke GH; Munder PG
Exp Hematol; 1983 Jul; 11(6):564-70. PubMed ID: 6617791
[TBL] [Abstract][Full Text] [Related]
11. Phospholipid-sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipid.
Helfman DM; Barnes KC; Kinkade JM; Vogler WR; Shoji M; Kuo JF
Cancer Res; 1983 Jun; 43(6):2955-61. PubMed ID: 6850605
[TBL] [Abstract][Full Text] [Related]
12. Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues.
Herrmann DB
J Natl Cancer Inst; 1985 Sep; 75(3):423-30. PubMed ID: 3861897
[TBL] [Abstract][Full Text] [Related]
13. Purging leukemic cells from simulated human remission marrow with alkyl-lysophospholipid.
Okamoto S; Olson AC; Vogler WR; Winton EF
Blood; 1987 May; 69(5):1381-7. PubMed ID: 3471282
[TBL] [Abstract][Full Text] [Related]
14. Induction of differentiation of cultured human and mouse myeloid leukemia cells by alkyl-lysophospholipids.
Honma Y; Kasukabe T; Hozumi M; Tsushima S; Nomura H
Cancer Res; 1981 Aug; 41(8):3211-6. PubMed ID: 6941852
[TBL] [Abstract][Full Text] [Related]
15. Clonogenicity of normal and malignant hematopoietic progenitor cells after exposure to synthetic alkyl-lymphospholipids.
Dulisch I; Neumann HA; Löhr GW; Andreesen R
Blut; 1985 Dec; 51(6):393-9. PubMed ID: 3865693
[TBL] [Abstract][Full Text] [Related]
16. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
17. Response of human multiple myeloma-derived cell lines to alkyl-lysophospholipid.
Glasser L; Dalton WS; Fiederlein RL; Cook P; Powis G; Vogler WR
Exp Hematol; 1996 Feb; 24(2):253-7. PubMed ID: 8641349
[TBL] [Abstract][Full Text] [Related]
18. Selective effect of O-alkyl lysophospholipids on the growth of a human lung giant cell carcinoma cell line.
Goto I; Hozumi M; Honma Y
Anticancer Res; 1994; 14(2A):357-62. PubMed ID: 8017834
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
20. Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents.
Pogrebniak A; Schemainda I; Azzam K; Pelka-Fleischer R; Nüssler V; Hasmann M
Eur J Med Res; 2006 Aug; 11(8):313-21. PubMed ID: 17052966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
